SEMERARO, FABRIZIO
 Distribuzione geografica
Continente #
NA - Nord America 1.780
EU - Europa 448
AS - Asia 197
SA - Sud America 2
Totale 2.427
Nazione #
US - Stati Uniti d'America 1.779
CN - Cina 121
DE - Germania 111
SE - Svezia 77
IT - Italia 73
SG - Singapore 67
FI - Finlandia 37
UA - Ucraina 32
RU - Federazione Russa 30
FR - Francia 28
GB - Regno Unito 19
BE - Belgio 16
IE - Irlanda 12
CZ - Repubblica Ceca 4
IN - India 3
NL - Olanda 3
HK - Hong Kong 2
VN - Vietnam 2
BR - Brasile 1
CA - Canada 1
CL - Cile 1
ES - Italia 1
IL - Israele 1
IS - Islanda 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
PK - Pakistan 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 2.427
Città #
Fairfield 302
Woodbridge 194
Houston 171
Chandler 147
Ashburn 138
Seattle 117
Cambridge 99
Wilmington 93
Jacksonville 85
Ann Arbor 70
Nyköping 69
Singapore 54
Bari 42
Roxbury 30
Lawrence 27
Beijing 18
Nanjing 18
Inglewood 17
Brussels 16
Des Moines 15
Grafing 14
Princeton 14
Strasbourg 13
Dublin 12
San Diego 11
New York 10
Hebei 9
Boardman 8
Helsinki 8
Nanchang 8
Brooklyn 7
Santa Clara 7
Espoo 6
Frankfurt am Main 6
Munich 6
Tianjin 6
Changsha 5
London 5
Paris 5
Shenyang 5
Brno 4
Redwood City 4
Rome 4
Bethlehem 3
Dearborn 3
Jiaxing 3
Pune 3
Zhengzhou 3
Chengdu 2
Dong Ket 2
Guangzhou 2
Hong Kong 2
Kunming 2
San Mateo 2
Shanghai 2
Altamura 1
Amsterdam 1
Augusta 1
Barletta 1
Bratislava 1
Changchun 1
Chicago 1
Chisinau 1
Chongqing 1
Cutrofiano 1
Francavilla Fontana 1
Hefei 1
Heze 1
Hounslow 1
Jinan 1
Keflavik 1
Kilburn 1
Lahore 1
Lorca 1
Los Angeles 1
Luxembourg 1
Mantova 1
Marseille 1
Mascalucia 1
Napoli 1
Prescot 1
Quanzhou 1
San Francisco 1
San Jose 1
Shijiazhuang 1
São Paulo 1
Tel Aviv 1
Toronto 1
Wuhan 1
Totale 1.962
Nome #
Platelet drop and fibrinolytic shutdown in patients with sepsis 128
Histones differentially modulate the anticoagulant and profibrinolytic activities of heparin, heparin derivatives and dabigatran. 125
Factor IX-Padua enhances the fibrinolytic resistance of plasma clots 121
Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation 114
Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors 110
Coagulopathy of Acute Sepsis 109
Grape intake reduces thrombin generation and enhances plasma fibrinolysis. Potential role of circulating procoagulant microparticles 105
Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots 100
Sepsis, thrombosis and organ dysfunction 96
Platelets and fibrinolysis 96
Platelet size for distinguishing between inherited thrombocytopenias and immune thrombocytopenia: a multicentric, real life study 89
Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor 88
Hyperprothrombinemia-induced APC resistance: differential influence on fibrin formation and fibrinolysis 87
FVIII/VWF complex displays a greater pro-hemostatic activity than FVIII preparations devoid of VWF. Study in plasma and cell-based models 87
Endothelial cells in the bone marrow of patients with multiple myeloma 84
Low D-dimer levels in sepsis: Good or bad? 82
Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential 81
Gene expression signature induced by grape intake in healthy subjects reveals wide-spread beneficial effects on peripheral blood mononuclear cells 80
Sepsis-associated disseminated intravascular coagulation and thromboembolic disease. 70
D-dimer corrected for thrombin and plasmin generation is a strong predictor of mortality in patients with sepsis 69
The role of thrombin activatable fibrinolysis inhibitor and factor XI in platelet-mediated fibrinolysis resistance: a thromboelastographic study in whole blood 66
Monoclonal antibodies targeting the antifibrinolytic activity of activated TAFI but not the anti-inflammatory activity on osteopontin and C5a 64
TISSUE FACTOR-EXPRESSING MONOCYTES INHIBIT FIBRINOLYSIS THROUGH A TAFI-MEDIATED MECHANISM, AND MAKE CLOTS RESISTANT TO HEPARINS 63
Evidence that fibrynolitic changes in paediatric obesity translate in a hypofibrinolytic state. Relative contribution of TAFI and PAI-1 59
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma 57
Extracellular histones promote fibrinolysis by single-chain urokinase-type plasminogen activator in a factor seven activating protease-dependent way 55
Coagulation-fibrinolysis changes during off-pump bypass: effect of two heparin doses 53
Diversi fattori contribuiscono alla ipofibrinolisi nei bambini obesi 46
Angiogenic endothelial cells within the bone marrow of multiple myeloma. A phenotypic and functional assessment 39
Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease 28
The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of LMWHs 26
Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A 18
Plasminogen activator-coated nanobubbles targeting cellbound β2-glycoprotein I as a novel thrombus-specific thrombolytic strategy 4
Totale 2.499
Categoria #
all - tutte 10.594
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.594


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020325 0 0 0 0 0 0 64 71 91 30 46 23
2020/2021380 23 40 20 21 54 27 29 43 42 51 16 14
2021/2022261 12 47 3 5 3 13 22 14 12 22 47 61
2022/2023386 56 47 23 36 30 41 5 52 82 1 9 4
2023/2024104 12 25 0 12 6 13 2 10 0 2 6 16
2024/2025187 23 2 40 48 9 52 13 0 0 0 0 0
Totale 2.499